Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › gemcitabine

gemcitabine

17 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of gemcitabine

370 trials tracked of gemcitabine: 64 in phase 3 or 4 and 39 with published results. The most-cited published study has 2857 citations.

370Trials tracked
64Phase 3 & 4
0Recruiting
39With published results
Phase distribution
Phase 3 64 Phase 2 281 Phase 1 23 Other / NA 2
  1. Phase 3 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Completed · 2,857 cited
  2. Phase 3 An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Completed · 2,575 cited
  3. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) Completed · 1,807 cited
  4. Phase 3 A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] Completed · 1,700 cited
  5. Phase 3 Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Completed · 1,136 cited
  6. Phase 3 Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) Completed · 1,070 cited
Show 44 more trials
  1. Phase 3 Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Completed · 791 cited
  2. Phase 3 Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) Completed · 648 cited
  3. Phase 3 Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) Completed · 497 cited
  4. Phase 3 First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin Completed · 475 cited
  5. Phase 3 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment Completed · 444 cited
  6. Phase 3 Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer Completed · 434 cited
  7. Phase 3 Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC Completed · 322 cited
  8. Phase 3 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Completed · 237 cited
  9. Phase 3 Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC) Completed · 218 cited
  10. Phase 3 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed · 194 cited
  11. Phase 3 Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Completed · 191 cited
  12. Phase 3 A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) Completed · 182 cited
  13. Phase 3 Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Completed · 172 cited
  14. Phase 3 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Completed · 165 cited
  15. Phase 3 QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas Completed · 164 cited
  16. Phase 3 A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Completed · 163 cited
  17. Phase 3 A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy Completed · 159 cited
  18. Phase 3 Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) Completed · 153 cited
  19. Phase 3 Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma Completed · 150 cited
  20. Phase 3 Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer Completed · 144 cited
  21. Phase 3 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Completed · 135 cited
  22. Phase 3 Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122) Completed · 108 cited
  23. Phase 3 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Completed · 58 cited
  24. Phase 3 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Completed · 56 cited
  25. Phase 3 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Completed · 50 cited
  26. Phase 3 Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) Completed · 41 cited
  27. Phase 3 The Bladder Instillation Comparison Study Completed · 39 cited
  28. Phase 3 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Completed · 36 cited
  29. Phase 3 Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma Completed · 35 cited
  30. Phase 3 A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine Completed · 24 cited
  31. Phase 3 Avelumab in First-line NSCLC (JAVELIN Lung 100) Completed · 22 cited
  32. Phase 3 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Completed · 13 cited
  33. Phase 3 Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study Completed · 10 cited
  34. Phase 3 A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Completed
  35. Phase 3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed
  36. Phase 3 Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Completed
  37. Phase 3 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Completed
  38. Phase 3 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma Completed
  39. Phase 3 EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX Completed
  40. Phase 3 Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma Completed
  41. Phase 3 A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer Completed
  42. Phase 3 A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Completed
  43. Phase 3 Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 Completed
  44. Phase 3 Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC Completed

Showing the 50 most-cited and recently-updated of 370 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Gemcitabine exposure associated with higher TP53 and PI3K pathway alterations in pancreatic ductal adenocarcinoma tumors
Gastroenterology Cohort
Gemcitabine exposure associated with higher TP53 and PI3K pathway alterations in pancreatic ductal adenocarcinoma tumors AI Finds Hidden Keys to Pancreatic Cancer Survival
This cohort study analyzed 184 pancreatic ductal adenocarcinoma tumors to assess the association between gemcitabine exposure and molecular …
Age and gemcitabine exposure drive distinct genetic patterns in pancreatic cancer, directly influencing survival rates for patients with key…
medRxiv Apr 16, 2026
Camonsertib plus gemcitabine shows preliminary activity in advanced solid tumors with DDR alterations
Oncology Phase I
Camonsertib plus gemcitabine shows preliminary activity in advanced solid tumors with DDR alterations New Drug Combo Helps Some Solid Tumors Grow Slower
This Phase Ib trial evaluated camonsertib plus gemcitabine in 76 patients with advanced solid tumors harboring DDR gene alterations.
This combination might offer a new hope for patients whose tumors have stopped responding to standard treatments.
Apr 16, 2026
Penpulimab plus chemotherapy significantly improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma
Oncology RCT
Penpulimab plus chemotherapy significantly improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma New drug plus chemo delays cancer growth in advanced nasopharyngeal cases
This randomized, double-blind phase 3 trial evaluated penpulimab combined with cisplatin/carboplatin and gemcitabine versus placebo plus che…
Adding penpulimab to chemotherapy delays cancer growth by nearly three months in advanced nasopharyngeal cases, offering new hope for patien…
Apr 13, 2026
Phase II trial finds adding gemcitabine to cisplatin-radiotherapy does not improve 2-year disease-free survival in muscle-invasive bladder cancer
Urology RCT
Phase II trial finds adding gemcitabine to cisplatin-radiotherapy does not improve 2-year disease-free survival in muscle-invasive bladder cancer Adding gemcitabine to cisplatin did not improve disease-free survival in bladder cancer patients
A Phase II randomized trial in 69 patients with pT2-pT3N0M0 muscle-invasive bladder cancer found similar 2-year disease-free survival (58.3%…
Adding gemcitabine to cisplatin radiotherapy did not improve disease-free survival for bladder cancer patients, with similar two-year rates …
Apr 8, 2026
Phase 3 trial of pembrolizumab plus chemo for advanced biliary tract carcinoma posts results
Neurology Phase III
Phase 3 trial of pembrolizumab plus chemo for advanced biliary tract carcinoma posts results Can adding pembrolizumab to standard chemo help people with advanced bile duct cancer?
A phase 3 randomized controlled trial in 1,069 participants with advanced biliary tract carcinoma compared first-line pembrolizumab plus…
A large trial of adding immunotherapy to standard chemo for advanced bile duct cancer is complete, but the results showing if patients live …
CT.gov Apr 2, 2026